Verastem reported $-21.3M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
AstraZeneca USD 7.46B 2.3B Sep/2026
Curis USD -12.3M 231K Sep/2023
Cytokinetics USD -160.3M 9.02M Jun/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
Incyte USD 778.57M 410.6M Jun/2026
Laboratory Of America USD 674.3M 93.4M Sep/2026
Novartis USD 8.62B 2.14B Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Roche Holding CHF 13.43B 744M Jun/2026
TG Therapeutics USD 89.8M 62.9M Sep/2026